Amneal Pharmaceuticals: UBS Buy Recommendation Provides the Foundation for Price Increase Above the 50-Day Moving Average and a Resistance Line!

Amneal Pharmaceuticals (AMRX) is a specialty pharmaceutical company that is looking forward to an exciting phase of accelerated product launches and targeted expansions in 2026. The last year, 2025, was already successful with revenue exceeding $3 billion, but the management expects even more for 2026. Recent news fully confirms this optimism, as the company successfully launched its first two inhalation products for respiratory therapy in the U.S. market in April 2026. However, a crucial growth driver is the neurology division, particularly in...